RxSight, Inc. Files 8-K on Financial Condition

Ticker: RXST · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1111485

Rxsight, Inc. 8-K Filing Summary
FieldDetail
CompanyRxsight, Inc. (RXST)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, 8-k

TL;DR

RxSight filed an 8-K on Jan 12th, reporting financial condition. No numbers yet.

AI Summary

RxSight, Inc. filed an 8-K on January 13, 2025, reporting on its Results of Operations and Financial Condition as of January 12, 2025. The filing does not contain specific financial figures or operational details beyond the reporting date and company information.

Why It Matters

This 8-K filing indicates a routine update on the company's financial status, which is important for investors to monitor for any significant changes or disclosures.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for reporting financial condition, with no immediate indication of adverse events or significant changes.

Key Players & Entities

  • RxSight, Inc. (company) — Registrant
  • January 12, 2025 (date) — Date of earliest event reported
  • January 13, 2025 (date) — Date of Report
  • 100 Columbia (address) — Principal Executive Offices
  • Aliso Viejo, California (location) — Principal Executive Offices
  • 92656 (zip_code) — Principal Executive Offices
  • (949) 521-7830 (phone_number) — Registrant's Telephone Number

FAQ

What specific financial information is being reported in this 8-K?

The filing indicates it is reporting on 'Results of Operations and Financial Condition' as of January 12, 2025, but the provided text does not contain specific financial figures or details.

When was this 8-K filing submitted to the SEC?

The filing was submitted on January 13, 2025.

What is the exact date of the earliest event reported in this filing?

The earliest event reported is as of January 12, 2025.

What is Rx Sight, Inc.'s principal executive office address?

The principal executive offices are located at 100 Columbia, Aliso Viejo, California, 92656.

What is the registrant's telephone number?

The registrant's telephone number, including area code, is (949) 521-7830.

Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-01-13 06:01:10

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, RxSight, Inc. (the "Company") issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2024 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit number Description 99.1 Press Release dated January 12, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RxSight, Inc. Date: January 13, 2025 By: /s/ Shelley Thunen Name: Shelley Thunen Title: Co-President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.